85 results
8-K
EX-99.1
IDYA
Ideaya Biosciences Inc
12 Mar 24
IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
6:04am
, in patients with MSI-high and MSS endometrial cancer
Potential first-in-class PARG inhibitor, in combination with anti-PD-1 therapy, targets two … capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
Forward-Looking Statements
This press release
8-K
EX-99.1
IDYA
Ideaya Biosciences Inc
20 Feb 24
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023
6:07am
preclinical research programs focused on pharmacological inhibition of several new targets for patients with solid tumors characterized by defined … discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
IDEAYA’s updated corporate
424B5
IDYA
Ideaya Biosciences Inc
19 Jan 24
Prospectus supplement for primary offering
5:15pm
-in-class synthetic lethality combination targets mechanistically complementary nodes of the MTAP methylation pathway—MAT2A and PRMT5—and is supported … Helicase inhibitor DC in high MSI tumors.
We have multiple wholly owned preclinical-stage programs on undisclosed targets to enable the next wave
8-K
EX-99.1
90jrxm
4 Dec 23
IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy® and IDE397 Combination in MTAP-Deletion Bladder Cancer
6:04am
8-K
EX-99.1
hulwg9
7 Nov 23
IDEAYA Biosciences, Inc. Reports Third Quarter 2023
6:01am
424B5
ljy1bv2ot3ol 3khf
25 Oct 23
Prospectus supplement for primary offering
9:45pm
424B5
54l190b
24 Oct 23
Prospectus supplement for primary offering
5:26pm
8-K
EX-99.1
br6dwl992ajvwbjwow
10 Aug 23
IDEAYA Biosciences, Inc. Reports Second Quarter 2023
6:01am
424B5
lwq qfjygd7cg
26 Jun 23
Prospectus supplement for primary offering
5:30pm
8-K
EX-99.1
t2j0xol5pi5634h 24
16 May 23
IDEAYA Expands Clinical Trial Collaboration and Supply Agreements with Pfizer
6:02am
8-K
EX-99.1
l9q7xpqauc4rbc5a4
9 May 23
IDEAYA Biosciences, Inc. Reports First Quarter 2023 Financial Results
6:01am
424B5
hscpgw0mtzg67m9b cr
25 Apr 23
Prospectus supplement for primary offering
7:35pm
424B5
8o6ypx
24 Apr 23
Prospectus supplement for primary offering
4:53pm
8-K
EX-99.1
jympy 6qu86y4bm
8 Nov 22
IDEAYA Biosciences, Inc. Reports Third Quarter 2022
6:02am